Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

CASI Pharmaceuticals (CASI) EBT Margin (2022 - 2025)

Historic EBT Margin for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to 259.54%.

  • Pharmaceuticals' EBT Margin fell 468300.0% to 259.54% in Q2 2025 from the same period last year, while for Jun 2025 it was 267.72%, marking a year-over-year decrease of 1559100.0%. This contributed to the annual value of 133.4% for FY2024, which is 553700.0% down from last year.
  • Latest data reveals that Pharmaceuticals reported EBT Margin of 259.54% as of Q2 2025, which was down 468300.0% from 161.94% recorded in Q1 2025.
  • In the past 5 years, Pharmaceuticals' EBT Margin ranged from a high of 48.01% in Q4 2023 and a low of 267.85% during Q1 2024
  • Over the past 4 years, Pharmaceuticals' median EBT Margin value was 90.79% (recorded in 2023), while the average stood at 128.37%.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by -1814400bps in 2024, then surged by 1059100bps in 2025.
  • Pharmaceuticals' EBT Margin (Quarter) stood at 145.03% in 2022, then skyrocketed by 67bps to 48.01% in 2023, then crashed by -343bps to 212.72% in 2024, then decreased by -22bps to 259.54% in 2025.
  • Its EBT Margin stands at 259.54% for Q2 2025, versus 161.94% for Q1 2025 and 212.72% for Q2 2024.